Spik Imm

Founded in 2021 by Truffle Capital and the Institut Pasteur, SpikImm focuses on developing human monoclonal antibodies (mAbs) to prevent COVID-19, specifically targeting immunocompromised patients who cannot generate a protective antibody response post-vaccination. The company's lead candidates, SPK001 and SPK002, have shown potent neutralization activity against SARS-CoV-2 and its variants in vitro, along with therapeutic efficacy in vivo in animal models. These candidates are designed as long-acting antibodies administered intramuscularly for pre-exposure prophylaxis. SpikImm has completed a phase 1 clinical study for SPK001 and plans to demonstrate its medical benefits in a phase 2 trial. Depending on the outcomes, the company may seek Emergency Use Authorization (EUA) in the second half of 2023. SpikImm operates in the biopharmaceutical sector, serving healthcare providers and patients, with a business model centered on clinical development and potential commercialization of its antibody therapies. The company generates revenue through partnerships, grants, and potential future sales of its therapeutic products. Keywords: monoclonal antibodies, COVID-19, immunocompromised, prophylaxis, SARS-CoV-2, clinical trials, biopharmaceutical, Truffle Capital, Institut Pasteur, SPK001.